Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Calvez

Showing results (131-140 of 329) with videos related to

Pageof 33
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 2, 2025
Utilizing HIV Proviral DNA to Assess for the Presence of HIV Drug ResistanceAnnemarie M Wensing, Charlotte Charpentier, Vincent Calvez, et al.
The Journal of Antimicrobial Chemotherapy|July 22, 2008
Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 TrialClaudine Duvivier, Jade Ghosn, Lambert Assoumou, et al.
Antiviral Therapy|May 17, 2007
Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patientsAnne-Genevieve Marcelin, Philippe Flandre, Carmen de Mendoza, et al.
Open Forum Infectious Diseases|November 29, 2023
Comparative Performance of Anyplex II HPV28 and Cobas 4800 Human Papillomavirus (HPV) Assays for High-Risk HPV Detection in Self-collected Anal SamplesGauthier Delvallez, Sokleaph Cheng, Stéphane Marot, et al.
Nature Communications|June 15, 2026
Cell polarity control by an unconventional G-protein complex in bacteriaCéline Dinet, Corinne Sebban-Kreuzer, Deborah Byrne-Kodjabachian, et al.
Emerging Infectious Diseases|May 23, 2020
Fatal Encephalitis Caused by Cristoli Virus, an Emerging Orthobunyavirus, FranceChristophe Rodriguez, Guillaume Gricourt, Melissa Ndebi, et al.
AIDS (London, England)|March 2, 2002
Final analysis of the Trilège induction-maintenance trial: results at 18 monthsPhilippe Flandre, François Raffi, Diane Descamps, et al.
The Journal of Antimicrobial Chemotherapy|September 4, 2008
Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 proteaseSidonie Lambert-Niclot, Philippe Flandre, Isabelle Malet, et al.
Antimicrobial Agents and Chemotherapy|November 28, 2007
Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavirSidonie Lambert-Niclot, Philippe Flandre, Ana Canestri, et al.
The Journal of Antimicrobial Chemotherapy|November 1, 2018
Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ARTAnne Derache, Collins C Iwuji, Siva Danaviah, et al.
Pageof 33

Showing results (131-140 of 329) with videos related to

Sort By:
Pageof 33
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 2, 2025
Utilizing HIV Proviral DNA to Assess for the Presence of HIV Drug ResistanceAnnemarie M Wensing, Charlotte Charpentier, Vincent Calvez, et al.
The Journal of Antimicrobial Chemotherapy|July 22, 2008
Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 TrialClaudine Duvivier, Jade Ghosn, Lambert Assoumou, et al.
Antiviral Therapy|May 17, 2007
Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patientsAnne-Genevieve Marcelin, Philippe Flandre, Carmen de Mendoza, et al.
Open Forum Infectious Diseases|November 29, 2023
Comparative Performance of Anyplex II HPV28 and Cobas 4800 Human Papillomavirus (HPV) Assays for High-Risk HPV Detection in Self-collected Anal SamplesGauthier Delvallez, Sokleaph Cheng, Stéphane Marot, et al.
Nature Communications|June 15, 2026
Cell polarity control by an unconventional G-protein complex in bacteriaCéline Dinet, Corinne Sebban-Kreuzer, Deborah Byrne-Kodjabachian, et al.
Emerging Infectious Diseases|May 23, 2020
Fatal Encephalitis Caused by Cristoli Virus, an Emerging Orthobunyavirus, FranceChristophe Rodriguez, Guillaume Gricourt, Melissa Ndebi, et al.
AIDS (London, England)|March 2, 2002
Final analysis of the Trilège induction-maintenance trial: results at 18 monthsPhilippe Flandre, François Raffi, Diane Descamps, et al.
The Journal of Antimicrobial Chemotherapy|September 4, 2008
Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 proteaseSidonie Lambert-Niclot, Philippe Flandre, Isabelle Malet, et al.
Antimicrobial Agents and Chemotherapy|November 28, 2007
Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavirSidonie Lambert-Niclot, Philippe Flandre, Ana Canestri, et al.
The Journal of Antimicrobial Chemotherapy|November 1, 2018
Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ARTAnne Derache, Collins C Iwuji, Siva Danaviah, et al.
Pageof 33